Bolt Biotherapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 88.1 million compared to USD 98.59 million a year ago. Basic loss per share from continuing operations was USD 2.36 compared to USD 2.97 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7929 USD | -3.90% | -37.07% | -29.21% |
15/05 | Top Midday Decliners | MT |
15/05 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.21% | 3.02Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-1.05% | 2.2TCr | |
-14.15% | 2.18TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- BOLT Stock
- News Bolt Biotherapeutics, Inc.
- Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022